Application of the woodchuck animal model for the treatment of hepatitis B virus-induced liver cancer

doi:10.4251/wjgo.v13.i6.509

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5920)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-3) series.

Item

Count

PDF

417

WORD

199

HTML

2840

Figures (1-3)

325

Tables (1-3)

367

Sum=4148

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

679

Download

325

Sum=1004

Publishing Process of This Article

Item

Count

Browse

373

Download

395

Sum=768

Jun 15, 2021 (publication date) through Apr 26, 2024

Times Cited of This Article

Times Cited (11)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastrointest Oncol. Jun 15, 2021; 13(6): 509-535
Published online Jun 15, 2021. doi: 10.4251/wjgo.v13.i6.509

Table 3 Immunomodulators evaluated in woodchucks for safety and antiviral efficacy against hepatitis B virus

Immunomodulator	Compound name	Brand name	Ref.
IFN-α			[192,226,228,229]
RIG-I/NOD2 agonist	SB 9200	Inarigivir	[227]
TLR7 agonist	GS-9620¹	Vesatolimod	[173]
	APR002		[225]
	RG7854		[38]
TLR8 agonist	GS-9688	Selgantolimod	[174]
TLR9 agonist	CpG-ODN		[234]
TLR9-dependent and -independent pathways	AIC649		[235]
	JVRS-100²		[175]
Viral gene expression inhibitor	RG7834		[226]
Immune checkpoint inhibitor	Anti-PD-L1		[236]

¹Treatment delayed hepatocellular carcinoma onset in woodchucks.

²Treatment inhibited formation of new liver tumors in woodchucks.

See text for more details. Anti-PD-L1: Antibody against programmed death-ligand 1; CpG-ODN: CpG oligodeoxynucleotide, a short single-stranded synthetic DNA molecule containing unmethylated deoxycytosine-deoxyguanosine (CpG) motifs; IFN-α: Interferon alpha; JVRS-100: Complex of non-coding plasmid DNA and cationic liposomes; NOD2: Nucleotide-binding oligomerization domain-containing protein 2; RIG-I: Retinoic acid-inducible gene I; TLR: Toll-like receptor.

Citation: Suresh M, Menne S. Application of the woodchuck animal model for the treatment of hepatitis B virus-induced liver cancer. World J Gastrointest Oncol 2021; 13(6): 509-535
URL: https://www.wjgnet.com/1948-5204/full/v13/i6/509.htm
DOI: https://dx.doi.org/10.4251/wjgo.v13.i6.509